Core Viewpoint - The ongoing controversy regarding the authenticity of collagen content in the "可复美胶原棒" product has sparked significant industry attention, with both 华熙生物 and 巨子生物 responding to the allegations made by 郝宇 and the testing institution involved [1][2]. Group 1: Company Responses - 华熙生物 issued a statement supporting 郝宇, indicating that they have conducted thorough evaluations and testing of the claims made against their products, and are willing to cooperate with regulatory bodies regarding the testing results [1]. - 巨子生物's 可复美 brand acknowledged the apology from the testing institution used by 郝宇 but stated their intention to pursue legal action against those spreading false information [2][3]. Group 2: Industry Implications - The dispute highlights the growing scrutiny within the medical aesthetics industry regarding product integrity and consumer trust, as both companies emphasize their commitment to transparency and consumer rights [2].

Core Viewpoint - The public dispute regarding the content of recombinant collagen in the product "Collagen Stick" from the brand Kefu Mei, owned by Giant Biological (02367.HK), has intensified, with accusations of misleading information about the actual collagen content [1][3]. Group 1: Company Response and Actions - Giant Biological received an apology from the testing agency used by the beauty blogger "Big Mouth Doctor" (Hao Yu) on May 30, and the company has sent products to multiple testing institutions for compliance checks [2][4]. - The company claims that multiple tests have shown collagen content greater than 0.1%, adhering to the standards set by the Chinese Pharmacopoeia [4]. - Giant Biological clarified that the rumors about the product "Collagen Stick 1.0" being taken off the shelves are false, stating it was a normal product iteration that began in April [6]. Group 2: Industry Context and Competitor Involvement - The controversy has drawn attention from competitors, notably Huaxi Biological, which publicly supported the claims made by "Big Mouth Doctor" and offered to assist in testing and regulatory communication [10]. - Huaxi Biological has criticized the overhyped claims surrounding recombinant collagen, suggesting that the industry is experiencing inflated expectations without sufficient scientific backing [13]. - The financial performance of Huaxi Biological has been declining, with a reported revenue of 5.371 billion in 2024, down 11.61% year-on-year, and a significant drop in net profit [13]. Group 3: Financial Performance of Giant Biological - Giant Biological has shown steady revenue growth from 1.19 billion in 2020 to 5.539 billion in 2024, with net profit increasing from 826 million to 2.062 billion during the same period [7]. - The Kefu Mei brand is a significant contributor to Giant Biological's revenue, accounting for 82% of total income in 2024, with a reported revenue of 4.542 billion [7]. - Concerns have been raised about the potential impact of the ongoing controversy on the company's performance during the critical 618 e-commerce promotion period [7].

6月1日晚间，A股玻尿酸巨头华熙生物（688363）在微信号发表了一份逾2700字的长文支"大嘴博士"。 声明称，"华熙生物已组织专家对郝宇博士提供的资料进行审慎评估和多方法的反复测试，同时， 华熙生物也已经得到了第三方机构的检测结 果。 但在相关企业的自我检测结论公布之前，华熙生物出于对商业文明的最后一丝维护，希望相关企业主动面对发展中的问题，诚实面对全社 会关切的产品诚信和价值承诺。如监管机构需要查阅相关检测报告，华熙生物将毫无保留地配合提供；如相关企业无法正视自身问题，华熙生 物也将向全社会公开相关检测结果。" 声明中，华熙生物提及与郝宇博士的关系时表示，"鉴于热心网络水军的提醒，经过华熙生物核实，由郝宇博士担任法定代表人的上海柳页医 创医疗科技服务有限公司由华熙生物参与的海南海熙私募股权投资基金与郝宇博士相关公司共同投资，设立于2024年10月，华熙生物在该基金 中占比32.4%。基于此，由郝宇博士担任法人的柳页医创属于华熙生态的重要成员，华熙生物理应予以坚定支持和依法保护。" 华熙生物官方告诫这家擅长网络水军运营的公司："汝求战，便得战!"如果你们想要一个"商战"，那一定会得一个真正的商战。 医美龙 ...

Core Viewpoint - The article discusses the rise and challenges faced by Juzhi Biotechnology, highlighting its rapid growth in the beauty industry and the recent controversies surrounding its flagship product, the collagen stick. Group 1: Company Overview - Juzhi Biotechnology, founded by Yan Jianya and Fan Daidi, has become a significant player in the beauty industry, with a market value exceeding 450 billion yuan in May 2023, making them the richest couple in Shaanxi [1][2]. - The company specializes in recombinant collagen products, leveraging advanced biotechnology to create products that mimic human collagen [5][6]. Group 2: Recent Controversies - In May 2023, Juzhi Biotechnology faced backlash from competitors and influencers, particularly regarding the safety and authenticity of its collagen stick product [3][11]. - A beauty influencer claimed that the collagen stick contained only 0.0177% of the advertised recombinant collagen, significantly below the stated minimum of 0.1% [11][14]. - Juzhi Biotechnology responded by asserting that their products met industry standards and were undergoing third-party testing to verify their claims [14][16]. Group 3: Market Impact - Following the controversies, Juzhi Biotechnology's stock price dropped over 8%, reducing its market capitalization from 909 billion HKD to 735 billion HKD within ten days [3][19]. - The company has seen significant sales from its collagen stick, generating over 5.15 billion yuan in revenue since its launch, accounting for 82% of the company's total revenue in 2024 [16][19]. Group 4: Competitive Landscape - The article highlights the competitive tension between Juzhi Biotechnology and other industry players, particularly Huaxi Biological, which criticized Juzhi's marketing tactics and product claims [3][19]. - Both companies have invested heavily in marketing, with Juzhi's marketing expenses exceeding 2 billion yuan in 2024, while Huaxi's were around 24.64 billion yuan [19].

6月1日，华熙生物官方公众号发布关于支持郝宇博士维护消费者权益的声明。当中介绍，华熙生物于5月26日收到郝 宇博士（网名大嘴博士）的求助，提出希望华熙生物提供检测技术资源和研究支持，并协助其与监管部门展开沟通。 针对相关要求，华熙生物组织了有关专家评估了郝宇博士提供的资料，在确认检测报告的真实性后，华熙生物立刻组 织了相关产品检测，现公开回应如下： 1、华熙生物已组织专家对郝宇博士提供的资料进行审慎评估和多方法的反复测试，同时，华熙生物也已经得到了第 三方机构的检测结果。但在相关企业的自我检测结论公布之前，华熙生物出于对商业文明的最后一丝维护，希望相关 企业主动面对发展中的问题，诚实面对全社会关切的产品诚信和价值承诺。如监管机构需要查阅相关检测报告，华熙 生物将毫无保留地配合提供；如相关企业无法正视自身问题，华熙生物也将向全社会公开相关检测结果。 2、郝宇博士作为行业资深研发和科普专家拥有广泛的行业认知度和影响力，相关行为是在有检测报告的情况下实名 公开对相关企业提出问题，属于以科学专业方法维护消费者的基本安全和相关权益。动用大量网络水军将产品质量和 诚信关切问题转移到"商战"、"黑公关"只会因低估网友智商遭 ...

Core Viewpoint - The article discusses the financial struggles and risks faced by Dongfang Yanmei, a medical aesthetics company attempting to go public in Hong Kong, despite the booming beauty industry in China. The company is heavily in debt and has reported significant losses, raising questions about its future profitability and the viability of its core product, XH301, which is still awaiting regulatory approval [2][12]. Group 1: Company Overview - Dongfang Yanmei, established in 2016, focuses on regenerative medical devices and special medical foods, and has recently submitted its IPO application to the Hong Kong Stock Exchange [3]. - The leadership team, averaging over 50 years of age, consists of veterans from traditional pharmaceutical companies who have shifted their focus to the medical aesthetics sector [4]. Group 2: Financial Performance - In 2023, Dongfang Yanmei reported total assets of 148.9 million RMB and total liabilities of 116.6 million RMB, resulting in a debt-to-asset ratio of 78%. By 2024, total liabilities are projected to rise to 195.8 million RMB, increasing the debt-to-asset ratio to 123% [6]. - The company has incurred losses exceeding 69.38 million RMB in 2024, with a gross margin of only 2.6% [7][9]. - Operating cash flow for 2024 is expected to be just 1.587 million RMB, while the net loss is projected at 69.38 million RMB, indicating severe liquidity issues [8]. Group 3: Product and Market Potential - The core product, XH301, is a regenerative medicine injectable designed to stimulate collagen regeneration, commonly referred to as "童颜针" (youthful needle) in the aesthetics market [10][11]. - The market for such products is growing, with XH301 showing promising clinical trial results, but competition is intensifying as several similar products are set to launch in the coming years [11][14]. Group 4: Risks and Challenges - The company acknowledges significant risks in its IPO prospectus, including the possibility of never achieving profitability, with a detailed risk factor section spanning 60 pages [12][14]. - Dongfang Yanmei's reliance on external financing and high R&D expenditures, which exceed 300% of its revenue, poses a fundamental conflict between technological aspirations and financial realities [9][10].

Core Insights - The "Global Brand China Online 500 Strong List" (CBI 500) highlights the importance of consumer purchasing behavior in evaluating brands, moving beyond traditional metrics like sales revenue [2][5] - The beauty industry is identified as having the highest "brand index" among daily consumer goods, with a clear trend towards brand competition concentrated among leading brands [11][14] - International brands continue to outperform domestic brands in overall scores and representation on the list, indicating a need for domestic brands to focus on brand building [11][14] Industry Trends - The beauty sector's CBI score reached 75.83 in Q1 2025, an increase of 2.82 from Q1 2023, reflecting a strong brand presence among top players [11] - The CBI index emphasizes quality over quantity, with a scoring system that includes brand awareness, novelty, loyalty, and reputation [7][11] - The online retail market in China is significant, with the beauty segment accounting for 64.35% of total online transactions, amounting to approximately 6910.52 million yuan in 2024 [5][11] Competitive Landscape - The latest Tmall sales data indicates a growing head effect, where leading brands are capturing more market share, pushing lower-quality products out of the market [3][15] - In the recent Tmall 618 event, brands like Proya and Lancôme achieved significant sales milestones, showcasing the competitive dynamics between domestic and international brands [15][20] - International brands are regaining market strength, with companies like L'Oréal reporting a 6.9% sales growth in Q1 2025, indicating a recovery in the Chinese market [20][21] Brand Development Strategies - Tmall is shifting its focus from low-price strategies to supporting quality brands, aiming to enhance brand loyalty and consumer engagement [22][24] - The platform is investing heavily in brand support initiatives, with a budget of 200 billion yuan aimed at fostering innovative and high-quality brands [22][25] - The competition is evolving beyond product offerings to include brand equity and market positioning, with both international and domestic brands needing to adapt to these changes [25]

Core Viewpoint - The article discusses the controversy surrounding the collagen product "胶原棒" from 巨子生物, highlighting concerns about the actual content of recombinant collagen being lower than advertised, which could impact consumer trust and company performance [4][6][15]. Company Analysis - 巨子生物's flagship product, "胶原棒," is projected to generate 4.5 billion yuan in revenue for 2024, representing a 62.9% year-on-year growth and accounting for 80% of the company's total revenue [4][15]. - The controversy began when a social media influencer claimed that the actual recombinant collagen content in "胶原棒" was only 0.0177%, significantly below the stated minimum of 0.1% [6][7]. - The company asserts that their products meet the industry standard, with multiple tests showing collagen content above 0.1% [6][7]. Industry Context - The issue of low recombinant collagen content points to broader challenges in the industry, including production limitations and the need for clearer regulatory standards for testing [8][9]. - The market for recombinant collagen has seen significant growth, with companies like 巨子生物 and 锦波生物 achieving substantial valuations due to the high demand for these products [10][11]. - The controversy could lead to a decline in consumer confidence, especially with the upcoming "618" shopping festival, which is crucial for sales [13][15]. Market Dynamics - The sales of "胶原棒" have been strong, with over 5.15 billion units sold since its launch, and the introduction of a new version is expected to further boost sales [15]. - Major players in the cosmetics and medical beauty sectors are increasingly investing in recombinant collagen products, indicating a trend towards expanding this market [15][16]. - The trust crisis surrounding recombinant collagen could have far-reaching implications for the entire industry, affecting not just 巨子生物 but also other companies involved in this segment [17][18].

Core Viewpoint - The recent controversy surrounding hyaluronic acid and recombinant collagen products has led to significant scrutiny and volatility for leading companies in the medical beauty biotechnology sector, including Huaxi Biological, Juzhi Biological, and Jinbo Biological [2][11]. Group 1: Controversy and Market Reactions - Huaxi Biological publicly criticized brokerage reports for promoting the "hyaluronic acid is outdated" narrative, suggesting that the recombinant collagen concept is being overly hyped [3][11]. - Juzhi Biological faced public backlash due to a report indicating that its product "Kefumei" contained only 0.0177% recombinant collagen, below the legal threshold of 0.1% [4][11]. - Jinbo Biological's stock price was affected by the overall negative sentiment in the collagen sector, experiencing a significant drop of 17.23% from its peak [5][7]. Group 2: Financial Performance - Huaxi Biological reported its worst performance since going public in 2024, with revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [9][10]. - Juzhi Biological achieved a revenue of 5.539 billion yuan in 2024, a year-on-year growth of 57.2%, but its core product's growth rate has been declining for four consecutive years [9][10]. - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, but its growth rate has also shown signs of slowing down [10]. Group 3: Industry Dynamics - The ongoing "ingredient dispute" highlights the competition between hyaluronic acid and recombinant collagen technologies, with Huaxi Biological emphasizing the scientific value of hyaluronic acid [11][13]. - The controversy may intensify competition in technology development, market promotion, and brand building within the medical beauty industry, pushing for more emphasis on product efficacy and scientific validation [13].

Core Viewpoint - The Ministry of Industry and Information Technology has announced the preliminary list of the first batch of key cultivation pilot platforms, with a total of 242 platforms selected nationwide, covering essential fields for high-quality development in manufacturing [1][3]. Summary by Relevant Sections Pilot Platforms Overview - A total of 242 pilot platforms have been selected, categorized as follows: 79 in raw materials industry, 62 in consumer goods industry, 60 in equipment manufacturing, 21 in information technology, 13 in emerging and future industries, and 7 in common demand fields [3]. Equipment Manufacturing Sector - In the equipment manufacturing sector, 8 instrument and meter pilot platforms have been included, such as: - China Sensor Valley Intelligent Sensor Pilot Platform - Automotive Sensor Pilot Platform - Instrument Functional Materials and Special Sensors Pilot Platform - High-Precision Grating Scale Manufacturing and Application Pilot Platform - Nuclear Power Plant Instrument Pilot Platform - Beijing Jingyi High-End Instruments and Meters Pilot Platform - Guangdong Precision Instruments Advanced Manufacturing Technology Pilot Platform - Mechanical Industry Instrument Comprehensive Research Institute MEMS Sensor Pilot Platform [3][4]. Consumer Goods Industry - In the consumer goods industry, 33 pharmaceutical pilot platforms have been selected, including: - Liaoning Shangyao Northern Pharmaceutical Chemical Pilot Platform - Gene Engineering Drug Clinical Test Sample Preparation Pilot Platform - Innovative Drug Pilot Platform - Various medical device pilot platforms such as the West Lake IBT Biological Intelligence Pilot Platform and Regenerative Medicine Technology and Material Transformation Pilot Platform [5][6]. Medical Devices Sector - The medical devices sector includes 7 pilot platforms, such as: - West Lake IBT Biological Intelligence Pilot Platform - Medical Device Preclinical Animal Testing Safety Efficacy Verification and Inspection Testing Pilot Platform - Blood Dialysis Machine Pilot Platform - Beijing High-End Medical Device CDMO Pilot Platform - Regenerative Medicine Technology and Material Transformation Pilot Platform [7][8].